Alimax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alimax

Quick Facts

Property Description
Active ingredient Telmisartan
Form Oral tablet
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Blood pressure management
Origin Synthetic benzimidazole derivative

What Type of Drug is Alimax (Telmisartan)?

Alimax is the trade name for a synthetic, prescription-only medicine whose active component is Telmisartan. It belongs to the high-level pharmacological class known as Angiotensin II Receptor Blockers (ARBs), functioning as a selective AT1 receptor antagonist. Telmisartan is chemically defined as a non-peptide benzimidazole derivative. This classification confirms the drug's specialized chemical structure and its high binding affinity for the receptor target.

This class of drug is fundamentally different from ACE inhibitors; while ACE inhibitors prevent the creation of the potent vasoconstrictor Angiotensin II, Telmisartan works by directly blocking the specific receptor where Angiotensin II acts on blood vessels. This action establishes Telmisartan's primary role in managing systemic vascular resistance.

Composition and Pharmaceutical Form

The medicine's composition is centered on the single active ingredient, Telmisartan, and is prepared for oral administration as a solid dosage form. Alimax is manufactured as an oral tablet that incorporates essential pharmaceutical excipients for stability and absorption within the digestive system. A differentiating feature of Telmisartan is its high lipophilicity (fat solubility), which contributes to its prolonged presence in the body, supporting a once-daily dosing regimen. While primarily available as a single-ingredient product, Telmisartan is also commonly formulated into fixed-dose combinations with a diuretic, such as Hydrochlorothiazide, to offer synergistic blood pressure management.

General Purpose and Physiological Role

The overall purpose of this medicine is to help manage and maintain healthy blood pressure levels in adults by acting on the vascular system. By blocking the AT1 receptor, Telmisartan achieves the sustained relaxation and widening of the arteries, a process that reduces systemic vascular resistance. This physiological action directly results in a consistent lowering of arterial pressure, which is crucial for alleviating the chronic strain placed upon the heart and the blood vessel network over time.

Regulatory References

  1. NIH DailyMed for Telmisartan

What side effects are possible with Alimax?

Possible Side Effects and Safety Information

The officially documented safety profile for Alimax (Telmisartan) is structured by regulatory bodies to classify potential adverse reactions based on frequency and affected body system. These classifications differentiate between common, generally manageable effects and serious, rare events, establishing a factual hierarchy of risk.


Frequency and System Classification

Adverse effects are categorized based on their incidence in clinical trials, using standardized regulatory terminology.

  • Common Reactions (may affect up to 1 in 10 people) typically include effects such as back pain, sinusitis, and diarrhea. Other commonly documented reactions are dizziness and general fatigue.
  • Uncommon Reactions (may affect up to 1 in 100 people) include anemia, hyperkalemia (high serum potassium), and hypotension (low blood pressure), often involving the vascular and metabolic systems.
  • Rare Reactions (may affect up to 1 in 1,000 people) include clinically significant events like angioedema (swelling of the face, throat, and limbs), anaphylactic reaction, and sepsis.

Serious Safety Constraints

Certain high-level safety constraints are formally mandated in regulatory labeling:

  • Pregnancy Contraindication: Telmisartan is contraindicated during the second and third trimesters of pregnancy due to documented fetal toxicity.
  • Hepatic Restriction: The medicine is contraindicated in patients with biliary obstructive disorders or severe hepatic impairment.
  • Time-Related Pattern: Hypotension may be more pronounced in susceptible patients at the initiation of treatment.

These constraints define the official boundaries for the medicine’s safe use, as directed by government authorities.

Overdose and Emergency Response

Overdose and when to seek help

The following information is derived exclusively from governmental regulatory documentation pertaining to Telmisartan (Alimax) overdosage.


Overdose Scope

Feature Description (Strictly Regulatory Language)
Documented overdose presentations The most likely presentation is hypotension (abnormally low blood pressure). Other documented signs include dizziness, tachycardia (rapid heart rate), and bradycardia (slow heart rate, potentially due to vagal stimulation).
Physiological systems affected Primarily the cardiovascular system and the renal system (potential for oliguria or anuria).
Population-specific overdose notes Infants with histories of in utero exposure must be closely observed for hypotension, oliguria, and hyperkalemia; potential neonatal adverse effects include renal failure and death.
When immediate medical help is required Urgent medical attention is required if overdosage leads to collapse, seizure, trouble breathing, or unresponsiveness.

Resulting Overdose Structure

Official overdose statements:

  • Hypotension is the most likely manifestation of overdosage, potentially coupled with tachycardia or bradycardia.
  • Immediate contact with emergency services is required if symptoms include collapse, seizures, or breathing difficulties.
  • Management is symptomatic and supportive, and hemodialysis is not effective for drug removal.

Connection to the overall overdose profile: Regulatory documents define the Telmisartan overdose profile by the exaggerated cardiovascular effect of hypotension, which is the primary manifestation requiring intervention. This risk dictates the emergency response, mandating that urgent medical attention be sought immediately when severe, life-threatening symptoms are present. Management procedures are explicitly constrained by the drug's properties, with regulatory text confirming that hemodialysis cannot effectively remove the substance.

Therapeutic Uses of Alimax

What Alimax Treats: Main Uses and Benefits

Alimax (Telmisartan) is commonly used to help with the long-term, chronic management of essential hypertension, which is a condition involving fluctuating manifestations of persistently elevated arterial pressure that is often without immediate physical symptoms. This therapy is relevant for easing the symptoms related to systemic imbalance caused by the chronic pressure load. The primary benefit is providing support that helps maintain a consistent blood pressure level, which contributes to easing the overall symptom load and the gradual physiological strain on the cardiovascular system.

The core indications for this medicine are managing high blood pressure and addressing the high risk for acute cardiovascular events in relevant patient groups. It is also applied in specific clinical settings to manage patients with Type 2 Diabetes Mellitus who have evidence of target organ damage.

“This medication is primarily a long-term protective therapy, assisting with the sustained management of systemic pressure that is essential for maintaining functional stability.”


Therapeutic Support and Risk Reduction

A key use of this medicine is applied across domains where additional symptomatic support is needed to reduce the risk of acute or disruptive episodes. It is relevant for managing patients who are classified as high risk for cardiovascular events, relevant in situations where patients experience conditions associated with systemic or localized discomfort. This preventative application offers supportive assistance against the risk of serious, acute events and helps maintain a sense of stability when symptoms are more noticeable, supporting against severe, acute symptoms. Furthermore, it supports the patient during difficult episodes by easing distress related to conditions marked by increased physiological stress, such as those associated with Type 2 Diabetes, providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Supports Management of Systemic Imbalance
Main Clinical Context Chronic, long-term cardiovascular risk management
Primary Symptom Targeted Persistently elevated arterial pressure
Core Patient Benefit Supports consistent control of elevated arterial pressure

Regulatory References

  1. NIH DailyMed drug information

Eligibility and Restrictions for Use

Alimax (Telmisartan) is officially approved for use primarily in adults for the management of high blood pressure and the reduction of cardiovascular risk. The eligibility to use this medicine is strictly defined by regulatory authorities and includes several exclusions and limitations based on age and pre-existing conditions.

Populations Not Eligible for Use (Contraindicated)

The medicine is absolutely contraindicated in specific patient groups:

  • Pregnancy: Strictly prohibited during the second and third trimesters. Use is also generally not recommended in the first trimester, and the medicine should be discontinued immediately upon detection of pregnancy.
  • Severe Hepatic Impairment: Patients with severe liver disease or conditions causing biliary obstructive disorders (e.g., cholestasis) must not use Alimax.
  • Hypersensitivity: Individuals with a known allergy or hypersensitivity to telmisartan or any component of the tablet.
  • Dual RAS Blockade: Patients with Diabetes Mellitus or moderate-to-severe renal impairment (GFR less than 60 mL/min/1.73 m^2) are contraindicated if they are also taking products containing Aliskiren.

Age and Condition-Based Restrictions

Population Group Official Eligibility Status
Children & Adolescents (< 18 years) Safety and efficacy have not been established; use is not recommended.
Mild to Moderate Hepatic Impairment Permitted, but the maximum daily dose is restricted to 40 mg.
Breastfeeding Women Not recommended.
Primary Aldosteronism Use is not recommended due to expected lack of response to this drug class.

These constraints ensure the medicine is only used in patient populations where its eligibility is formally established by regulatory bodies.

What should I know about interactions with other medicines?

The official regulatory profile for Alimax (Telmisartan) interactions is defined by specific pharmacodynamic and pharmacokinetic considerations documented in government labels.

The most significant restriction is the formal contraindication against co-administering Telmisartan with Aliskiren in patients with diabetes mellitus or those with moderate-to-severe renal impairment.

Regulatory sources also advise against the dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS), such as combining Telmisartan with an ACE inhibitor, due to the documented increase in the risks of hyperkalemia, hypotension, and renal function changes.

Official Interaction Statements

  • Co-administration with Lithium or Digoxin is officially associated with an increase in the plasma concentrations of those agents, necessitating monitoring of serum levels. For Digoxin, this effect is attributed in part to Telmisartan's status as an inhibitor of the P-glycoprotein (P-gp) transporter.
  • Combining Telmisartan with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may result in a documented loss of the expected antihypertensive effect and an increased risk of renal impairment.
  • Products containing potassium supplements or potassium-sparing diuretics can contribute to hyperkalemia and are recommended to be used with caution.
  • The administration of Telmisartan is flexible, as official documents state the tablet may be taken with or without food.

Mechanism of Action

Modulating Specific Receptor Systems

Alimax primarily works by selectively engaging key receptor sites within defined neural or humoral pathways. This targeted interaction modifies the receptor's activity—either dampening excessive signals or enhancing necessary function—representing the initial molecular step that alters signaling dynamics.


Regulating Signal Transduction Cascades

Following receptor binding, the drug modifies the subsequent intracellular signal transduction cascades, influencing secondary messenger systems. This interference helps to limit the propagation of overactive signaling sequences throughout the cell, a result that modulates subsequent cellular activity.


Influencing Core Physiological Feedback

The resulting cellular modulation helps to modulate signaling within regulatory feedback loops that govern central and/or peripheral systems. By influencing these core mechanisms, Alimax influences the magnitude of physiological responses driven by pathway activity, which determines the resulting functional consequences.

Dosage and Administration Information

Administration Route and Frequency

Alimax (Telmisartan) is for oral administration as a tablet. The dosing schedule for approved uses is once daily, a frequency that supports the continuous, long-term management of chronic conditions.

Labeled Dosing Regimens

For managing essential hypertension, the common starting dose is 40 mg daily, though a lower initial dose of 20 mg may be used in certain patients. The dose is adjusted based on individual response within a typical maintenance range of 20 mg to 80 mg once per day. The maximal recommended daily dose for all indications is 80 mg. For the fixed-dose regimen intended for cardiovascular risk reduction, the dose is standardized at 80 mg once daily. It typically takes four to eight weeks after initiation or adjustment to achieve the medicine's maximal therapeutic effect.

Contextual Use and Special Instructions

The medicine is labeled to be administered with or without food, providing flexibility in the daily regimen. Tablets must be swallowed whole with liquid. Due to the tablet’s sensitivity to moisture, it must remain in the sealed blister packaging until immediately prior to ingestion. If a dose is missed, the recommended procedure is to take it when remembered, but to skip the dose if it is almost time for the next scheduled dose, thereby avoiding a double dose.

Dosing for Specific Populations

No initial dose adjustment is required for older adult (geriatric) patients. However, for patients with mild to moderate hepatic impairment, the total daily dose must not exceed 40 mg. Use in the pediatric population is not recommended as safety and efficacy have not been established.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Trials

According to the trials, research explored the compound's use in pain management in randomized, controlled trials (RCTs) involving over 2,000 adult participants experiencing acute musculoskeletal discomfort. Studies examined the measurements related to reduced pain over a four-week trial. Researchers evaluated the time to reported relief and monitored the duration of reduced symptoms.


Focus Areas of Research

1. Post-Surgical Recovery

Research focused on recovery time measurements following minor orthopedic procedures. The study protocol included specific guidelines regarding the types of procedures and follow-up monitoring. The study detailed the compound's administration within a controlled clinical setting.

2. Chronic Pain Management (Combination Therapy)

Trials also examined the compound when studied alongside an existing standard-of-care medication for chronic lower back discomfort. Studies compared the results of this combination versus other treatments involving only the standard-of-care medication.

3. Safety Profile (Subgroups)

Clinical trials included a subgroup analysis of people with mild liver issues. Additionally, studies excluded participants who were taking certain medications, such as high-dose anticoagulants. This was done to monitor potential interactions and side effects in a controlled environment. Studies monitored measurements related to patient mobility in the combination group.


Summary of Findings

The overall evidence remains limited, and results varied between the studies analyzed. No definitive conclusions can be drawn regarding the superiority of the compound. Research continues to explore the full range of observations and interactions.

Key Studies & References

  1. Efficacy and Safety of the Combination of Diclofenac and Thiocolchicoside in the Treatment of Low Back Pain and Other Conditions: Systematic Review of the Literature

Frequently Asked Questions (FAQ)

Common questions about Alimax (FAQ)


Q: How quickly does Alimax leave the system after the last dose?

Official pharmacokinetic data indicates that the medicine has a terminal elimination half-life of approximately 24 hours. This time frame means the active component is eliminated gradually from the body over about a day. This long elimination rate supports the once-daily dosing regimen.


Q: Is it common for the beneficial effects of Alimax to fade over time?

Studies documented in official regulatory sources show that the blood pressure lowering effect was maintained for at least one year in long-term non-placebo-controlled studies. This evidence suggests that the intended therapeutic effect is generally sustained over time with continuous use.


Q: Is it normal to feel slightly dizzy or drowsy when first starting Alimax?

Regulatory documents list both dizziness (a common adverse reaction) and somnolence (drowsiness) as potential side effects. These effects are often most noticeable at the beginning of treatment.


Q: Are there any officially documented long-term side effects associated with Alimax use?

Adverse reactions are collected even after the medicine is approved through a process called post-marketing surveillance. Rare effects identified through this monitoring process, which can occur long after initial use, include face edema (swelling of the face) and rhabdomyolysis (a type of muscle breakdown).


Q: Are there known interactions between Alimax and common pain relievers like ibuprofen or acetaminophen?

Regulatory documents contain warnings about combining the medicine with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a class that includes ibuprofen. However, acetaminophen is not specifically listed in the official interaction statements.


Q: Does Alimax interact with any popular vitamin or herbal supplements?

Official information indicates that caution is needed regarding use of the medicine with products such as potassium supplements or potassium-sparing diuretics. This is due to the potential risk of high potassium levels (hyperkalemia). No general warnings are given for all herbal supplements.


Q: Can taking Alimax affect the results of common laboratory blood tests?

Clinically relevant changes in standard laboratory parameters are rarely associated with the medicine's use. Regulatory information indicates that minor changes have been observed, such as small decreases in hemoglobin and increases in creatinine (a kidney function marker).


Q: Is it generally acceptable to drive or operate machinery while taking Alimax?

Official patient counseling information states that the medicine can potentially cause side effects like dizziness or lightheadedness. Official sources indicate that operating a car or heavy machinery is generally discouraged until the individual knows how the medicine affects them, due to this risk.


Q: Can Alimax be used by patients with pre-existing kidney or liver conditions?

Regulatory documents state that no dose adjustment is necessary for patients with certain degrees of decreased renal (kidney) function. However, the medicine is contraindicated (avoided) in patients who have severe hepatic impairment (severe liver disease) or biliary obstructive disorders.


Q: Can patients with a history of heart problems typically use Alimax?

One of the official approved indications for the medicine is lowering the risk of death, stroke, or heart attack in specific adult populations. This risk reduction is targeted at individuals with a documented history of heart problems, such as coronary artery disease.


Q: What is known about the long-term research or surveillance of Alimax after its approval?

Official regulatory bodies maintain a continuous system for collecting and reporting adverse effects after a medicine is approved. This post-marketing surveillance system is used to identify any rare or delayed reactions, which are then added to the official product label.


Q: Were the clinical trials for Alimax conducted on a diverse patient population?

Clinical studies included over 3,700 patients across various trials. Data analysis showed that the medicine's main effect is not generally influenced by a patient's age, gender, weight, or body mass index. However, the blood pressure lowering effect may be less pronounced in black patients.


Q: Is Alimax considered a long-term treatment or a short-course therapy?

Official product information classifies the medicine as being intended for the long-term management of chronic conditions, such as high blood pressure. It is not designed to be a temporary or short-course therapy.


Q: Does Alimax need to be taken continuously to be effective?

As the medicine is intended to control chronic high blood pressure but not cure it, official guidance indicates that the medicine is meant to be taken continuously. The beneficial effects are sustained only through continuous administration.


Q: Do the potential side effects of Alimax usually start right away?

Many potential adverse reactions, including low blood pressure (hypotension) and dizziness, are reported as being most likely to occur at the beginning of treatment. This is also true following any dose increase.


Q: Are there any known side effects of Alimax that are delayed and appear much later?

Some adverse effects are only identified through post-approval surveillance because they are rare or occur over a long period. These delayed effects reported include conditions such as face edema (swelling) and rhabdomyolysis.


Q: Do side effects associated with Alimax usually lessen after the first week of use?

Regulatory documentation generally describes adverse experiences as mild and transient in nature. However, the documentation does not provide a specific timeline for when all side effects may lessen.


Q: Does Alimax cause changes in appetite or weight in some patients?

Changes in appetite and weight gain are noted in official regulatory adverse event reporting sections. These are considered potential side effects that have been reported by patients.


Q: Can Alimax affect sleep patterns?

Adverse reactions reported in clinical trials include effects on the central nervous system. Specifically, insomnia (difficulty sleeping) and somnolence (drowsiness) are listed as potential side effects.


Q: Is it safe to consume alcohol in general while taking Alimax?

Official patient counseling information warns that Telmisartan and alcohol may have an additive effect in lowering blood pressure. This effect may increase the risk of symptoms like dizziness, lightheadedness, or fainting.

How should Alimax be stored and disposed of?

Official Storage and Disposal Requirements for Alimta (pemetrexed disodium)

Official regulatory documents define strict conditions for the storage, stability, and disposal of this product.

Storage Conditions

Product State Temperature Requirement Stability Constraint
Unreconstituted Vial Controlled Room Temperature (Below 30 C) Must not be frozen.
Prepared Solution Refrigerated (2 C to 8 C) Must be used or discarded within 24 hours.

Handling and Disposal

The product is classified as a hazardous drug, mandating compliance with special handling and disposal procedures by professional personnel. When preparing the solution, only specific diluents, such as 0.9% Sodium Chloride Injection, USP, are allowed; calcium-containing diluents must not be used. Any unused portion of the medication, along with the vial, must be discarded according to these special disposal rules after the 24-hour stability window has passed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alimax found in:

A-Z Index: